|
Water-Soluble Azole Phase II: Pharmakokinetics, Safety and QT Analysis (click for details) |
|
|
|
Comparison of the in vitro activity of BAL4815 and Fluconazole against Cryptococcus neoformans (click for details) |
|
|
|
Effect of BAL8557, a Water-Soluble Azole Pro-Drug (WSA), on the Pharmacokinetics of S- and R-Warfarin (click for details) |
|
|
|
“ IN VITRO” ACTIVITY OF BAL4815 (a new azole) AGAINST FILAMENTOUS FUNGI (click for details) |
|
|
|
Effect of BAL8557, a Water-Soluble Azole Pro-Drug (WSA), on the Pharmacokinetics of Tacrolimus (click for details) |
|
|
|
In vitro activity of BAL4815, a new water-soluble broad spectrum triazole, against opportunistic filamentous and dimorphic fungi (click for details) |
|
|
|
Effect of Rifampicin on the Pharmacokinetics of BAL4815 at Steady State after Multiple Oral Daily Doses of BAL8557 (WSA) and Rifampicin (click for details) |
|
|
|
Effect of Ketoconazole on the Pharmacokinetics of BAL4815 at Steady State after Multiple Oral Daily Doses of BAL8557 (WSA) and Ketoconazole (click for details) |
|
|
|
In Vitro Activity of BAL4815 against Zygomycetes (click for details) |
|
|
|
In vitro activity of a new triazole, BAL8557, against Histoplasma capsulatum isolates from patients who failed fluconazole therapy (click for details) |
|
|
